sotalol + amiodarone

This entry refers to the standard-of-care rhythm control arm in the Flec-CAD Phase 4 clinical trial sponsored by Universitaire Ziekenhuizen KU Leuven. In this trial, patients with atrial fibrillation and stable coronary artery disease are randomized to receive either flecainide or a standard rhythm-control drug, which is defined as either sotalol or amiodarone based on physician preference. Sotalol is a non-selective beta-adrenergic receptor blocker that also possesses Class III anti-arrhythmic properties by blocking the rapid component of the delayed rectifier potassium current (IKr). Amiodarone is a broad-spectrum Class III anti-arrhythmic agent that exhibits electrophysiological characteristics of all four Vaughan Williams classes, including sodium channel blockade (Class I), non-competitive anti-sympathetic action (Class II), potassium channel blockade (Class III), and calcium channel blockade (Class IV). Both agents are used to maintain sinus rhythm in patients with symptomatic atrial fibrillation.

Other names

Standard rhythm-control therapyStandard rhythm-control drugsClass III anti-arrhythmic drugs